Study of Undertreatment of Patients With Dyslipidemia in Bulgaria
Completed
- Conditions
- Dyslipidemia
- Registration Number
- NCT01075594
- Lead Sponsor
- AstraZeneca
- Brief Summary
The purpose of this study is to establish the proportion of Bulgarian patients on lipid-lowering pharmacological treatment reaching the LDL-C goals according to the Fourth Joint European Task Force guidelines.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 2500
Inclusion Criteria
- Lipid lowering drug treatment for at least 3 months, with no dose change for a minimum of 6 weeks
- Signed Informed Consent
Exclusion Criteria
- Informed Consent not provided
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The number and percentage of patients achieving the LDL-C goals, according to the Fourth Joint European Task Force guidelines 6 months - one visit only, no follow-up visits
- Secondary Outcome Measures
Name Time Method The number and percentage of subjects achieving the LDL-C goals, according to the Fourth Joint European Task Force guidelines for several subject subsets 6 months - one visit only, no follow-up visits The number and percentage of subjects achieving LDL-C goals according to the NCEP ATP III / 2004 updated 2004 NCEP ATP III guidelines, overall and for several subject subsets 6 months - one visit only, no follow-up visits The number and percentage of subjects achieving the non HDL-C goals according to the NCEP ATP III/updated 2004 NCEP ATP III/national guidelines [<130mg/dL (3,37mmol/L)], in the following sub-population: patients with fasting triglycerides >200 mg/dL 6 months - one visit only, no follow-up visits
Trial Locations
- Locations (1)
Research Site
🇧🇬Veliko Turnovo, Bulgaria